ArticleHuman gene therapy2012
Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy.
Article in Human gene therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 42 citations in OpenAlex.
- Anti-cancer efficacy of combined vaccine-strain measles and mumps viruses against colorectal cancer: an experimental study.Molecular biology reports · 2026Article
- Oncolytic viruses in head and neck cancer: therapeutic promise and translational challenges.Frontiers in immunology · 2026Review
- Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis.Molecular therapy oncolytics · 2023Article
- Nectins and Nectin-like Molecules in Colorectal Cancer: Role in Diagnostics, Prognostic Values, and Emerging Treatment Options: A Literature Review.Diagnostics (Basel, Switzerland) · 2022Review
- Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.Leukemia · 2020Article
- Engineering and combining oncolytic measles virus for cancer therapy.Cytokine & growth factor reviews · 2020Review
- Efficient Delivery and Replication of Oncolytic Virus for Successful Treatment of Head and Neck Cancer.International journal of molecular sciences · 2020Review
- Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9.Molecular therapy oncolytics · 2020Article
- Virotheranostics, a double-barreled viral gun pointed toward cancer; ready to shoot?Cancer cell international · 2020Review
- Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma.Pharmaceutical medicine · 2019Review
- Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials.Clinical and translational medicine · 2018Review
- Potential and clinical translation of oncolytic measles viruses.Expert opinion on biological therapy · 2017Review
- The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications.Annual review of physiology · 2017Review
- Review
- The current status of oncolytic viral therapy for head and neck cancer.World journal of otorhinolaryngology - head and neck surgery · 2016Review
- The use of the NIS reporter gene for optimizing oncolytic virotherapy.Expert opinion on biological therapy · 2016Review
- Oncolytic virotherapy for head and neck cancer: current research and future developments.Oncolytic virotherapy · 2015Review
- Advances in the design and development of oncolytic measles viruses.Oncolytic virotherapy · 2015Review
- Review
- Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.Frontiers in immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Oncolytic measles virus (MV) encoding the human thyroidal sodium iodide symporter (MV-NIS) has proved to be safe after intraperitoneal or intravenous administration in patients with ovarian cancer or multiple myeloma, respectively, but it has not yet been administered through intratumoral injection in humans. Squamous cell carcinoma (SCC) of the head and neck (SCCHN) usually is locally invasive and spreads to the cervical lymph nodes, which are suitable for the intratumoral administration of oncolytic viruses. To test whether oncolytic MV is an effective treatment for SCCHN, we used oncolytic MV-NIS to infect SCCHN in vitro and in vivo. The data show that SCCHN cells were infected and killed by MV-NIS in vitro. Permissiveness of the tumor cells to MV infection was not affected by irradiation after viral addition. Monitored noninvasively through radioiodine-based single-photon emission computed tomography/computed tomography, intratumorally virus-delivered NIS has concentrated the radioiodine in the MV-NIS-treated tumors in the FaDu mouse xenograft model of human SCCHN, and the antitumor effect could be boosted significantly (p<0.05) either with concomitant cyclophosphamide therapy or with appropriately timed administration of radioiodine (131)I. MV-NIS could be a promising new anticancer agent that may substantially enhance the outcomes of standard therapy after intratumoral administration in patients with locally advanced SCCHN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.